NCT07569315Not yet recruitingPhase 2
Successive Doses of GnRH Agonist Versus Single Dose of GnRH Agonist to Trigger Ovulation in Hyper-responders Undergoing IVF Cycle : A Randomized Controlled Study.
Bedaya Hospital1 site in 1 country190 target enrollmentStarted: June 1, 2026Last updated:
Conditions
Interventions
Drugs
Trial Snapshot
- Phase
- Phase 2
- Status
- Not yet recruiting
- Sponsor
- Enrollment
- 190
- Locations
- 1
- Primary Endpoint
- Metaphase-II oocytes rate
Study Overview
Brief Summary
The aim of this randomized controlled study is to compare the efficacy of three successive doses of a GnRH agonist ( administered 36 , 24 and 12 hours before oocyte retrieval ) with a single dose of a GnRH agonist ( administered 36 hours before oocyte retrieval ) in triggering ovulation in hyper-responders
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel
- Primary Purpose
- Treatment
- Masking
- Single (Outcomes Assessor)
Eligibility Criteria
- Ages
- 18 Years to 40 Years (Adult)
- Sex
- Female
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •GnRH antagonist IVF cycle
- •Hyper-responders to induction of ovulation
Exclusion Criteria
- •Hypogonadotrophic hypogonadism
- •Endometriosis
- •History of recurrent abortion
Arms & Interventions
Single dose GnRH agonist
Active Comparator
A single dose of GnRH agonist is administered 36 hours before oocyte retrieval
Intervention: Single dose GnRH agonist (Drug)
Successive doses GnRH agonist
Experimental
Three successive doses of GnRH agonist are administered 36 , 24 and 12 hours before oocyte retrieval
Intervention: Successive doses GnRH agonist (Drug)
Outcomes
Primary Outcomes
Metaphase-II oocytes rate
Time Frame: Ten to fifteen days after starting ovarian stimulation
Number of MII oocyte/ number of cumulus oocyte complex
Secondary Outcomes
- Clinical pregnancy rate(Five weeks after embryo transfer)
- Ongoing pregnancy Rate(Eighteen weeks after embryo transfer)
Investigators
Study Sites (1)
Loading locations...
Similar Trials
Not yet recruiting
Not Applicable
A Randomized Open-Label Trial Comparing GnRH Antagonist Monotherapy versus Add-Back Therapy(GnRH Antagonist with estrogen+progesterone)in Women with Uterine Fibroids and Abnormal Uterine Bleeding: Evaluation of Clinical and Bone Health OutcomesCTRI/2026/01/101789Dr Shalini Shukla136
Not yet recruiting
Phase 4
Options to Increase IVF SuccessCTRI/2024/03/063849NA100
Not yet recruiting
Phase 2/3
A Study Comparing an Oral Tablet (Elagolix) and an Injectable Hormone Blocker to Prevent Early Hormone Rise in Women Undergoing IVF Treatment.CTRI/2026/03/105423Dr Kundan V Ingale150
Not yet recruiting
Phase 3 4
To study the effects of gonadotropin with clomiphene citrate as compared to gonadotropin with letrozole in conception of infertile women.CTRI/2025/03/081960JNMC WARDHA120
Unknown
Not Applicable
三月剂型 GnRHa 与一月剂型 GnRHa 治疗中枢性性早熟的疗效及不良反应ChiCTR2300077931自筹